Is PFNA exposure associated with insulin resistance and hepatic metabolic disruption?

Perfluorononanoic acid (PFNA), a long-chain perfluoroalkyl substance (PFAS), is increasingly recognized for its role in altering human metabolic health. Research indicates that exposure to this persistent chemical is associated with measurable changes in glucose regulation and liver function, particularly through pathways involving systemic inflammation and hepatic signaling.

Clinical and metabolic evidence

Epidemiological data, including longitudinal analysis of NHANES cohorts, consistently link serum PFNA levels to markers of metabolic dysfunction in adults.

• Glucose Regulation: Higher concentrations of PFNA are associated with increased fasting plasma glucose and higher HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores. In specific cohorts, PFNA exposure has been correlated with a higher Triglyceride-Glucose (TyG) index, a reliable surrogate for insulin resistance.
• Liver Injury Markers: Studies spanning 2009–2018 show a positive correlation between PFNA levels and elevated liver enzymes, specifically alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT). These elevations are clinical indicators of hepatocyte injury and are often precursors to nonalcoholic fatty liver disease (NAFLD).

Mechanistic explanations

The disruption of metabolic signaling by PFNA occurs through both direct hepatic interference and indirect inflammatory pathways.

• Hepatic Signaling: PFNA acts as a ligand for peroxisome proliferator-activated receptor alpha (PPAR-α). In animal models, this activation disrupts bile acid (BA) and cholesterol homeostasis by downregulating biosynthetic enzymes like Cyp7a1 and transporters such as the sodium-taurocholate cotransporting polypeptide (NTCP). This can lead to cholestasis and the accumulation of lipids within the liver.
• Systemic Inflammation: The association with insulin resistance is heavily mediated by pro-inflammatory cytokines. Research suggests that PFNA exposure increases levels of CCL4, IL-1β, IL-9, and TNF-α. This inflammatory state contributes to impaired insulin signaling and reduced glucose uptake, potentially through mechanisms such as GM3 ganglioside stabilization, which has been observed in related PFAS compounds.

Clinical implications

For older individuals, these findings suggest that PFAS exposure may exacerbate age-related metabolic decline. The cumulative effect of PFNA on hepatic signaling and insulin sensitivity may increase the risk of developing type 2 diabetes or progressing toward advanced liver steatosis. Monitoring liver enzyme profiles and glucose markers is particularly relevant in populations with high suspected environmental exposure.

Bottom line

PFNA exposure is significantly associated with insulin resistance and hepatic metabolic disruption. This relationship is driven by PPAR-α-mediated liver injury and systemic immune-mediated inflammation, manifesting clinically as elevated liver enzymes and impaired glucose homeostasis.